Company: Rigel Pharmaceuticals
Starting stock price: $11.89
Ending stock price: $25.39
Percent Change: 113.54%
Details: Rigel has a number of drug candidates in its pipeline. R788 is in Phase II trials for rheumatoid arthritis, ITP and B-cell lymphoma. It's also partnering with Merck Serono on the Phase II compound R763 for solid tumors andÂ leukemia. Additionally, Rigel and Pfizer are developing R343 for asthma.
Merck Serono exercises option to Rigel's R763. Report
Serono seals oncology drug pact with Rigel. Report